Read More Pharma Industry News Seaport Therapeutics seeks $212m IPO as neuropsychiatry biotech window reopens Seaport’s IPO tests biotech appetite before key depression data. Here’s why SPTX, PureTech, and psychiatry investors are watching. byPallavi MadhirajuApril 28, 2026